|
1
|
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
|
Ophthalmology
|
2016
|
1.04
|
|
2
|
Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.
|
Am J Ophthalmol
|
2015
|
1.02
|
|
3
|
Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema.
|
Am J Ophthalmol
|
2014
|
0.88
|
|
4
|
Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
|
Ophthalmology
|
2016
|
0.88
|
|
5
|
Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
|
Ophthalmology
|
2015
|
0.85
|
|
6
|
Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials.
|
Ophthalmology
|
2014
|
0.83
|
|
7
|
Uncorrected Hyperopia and Preschool Early Literacy: Results of the Vision in Preschoolers-Hyperopia in Preschoolers (VIP-HIP) Study.
|
Ophthalmology
|
2016
|
0.79
|
|
8
|
Endothelial PAS domain-containing protein 1 (EPAS1) gene polymorphisms and response to anti-VEGF therapy in the comparison of AMD treatments trials (CATT).
|
Ophthalmology
|
2014
|
0.78
|
|
9
|
Timely implementation of a retinopathy of prematurity telemedicine system.
|
J AAPOS
|
2016
|
0.77
|
|
10
|
Author reply: To PMID 23337555.
|
Ophthalmology
|
2014
|
0.75
|
|
11
|
Baseline Choroidal Thickness as a Predictor for Treatment Outcomes in Central Retinal Vein Occlusion.
|
Am J Ophthalmol
|
2016
|
0.75
|